Scientists are one step closer to using CRISPR gene editing on humans, with a US federal advisory panel approving the use of the technique for a study led by the University of Pennsylvania.

The scientists are seeking to use the CRISPR-Cas9 technique to create genetically altered T cells – white blood cells that play an important role in our immune system – that are more effective at fighting cancer cells in patients with melanoma, multiple myeloma, and sarcoma.

“Our preliminary data suggests that we could improve the efficacy of these T cells if we use CRISPR,” lead researcher Carl June told the National Institute of Health’s (NIH) Recombinant DNA Advisory Committee (RAC) on Tuesday.

Read more